Trial Profile
SNIPP study - A investigator initiated phase II study of Sunitinib in patients with recurrent paraganglioma/pheochromocytoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- Acronyms SNIPP
- 25 Jan 2023 Status changed from active, no longer recruiting to completed.
- 29 Nov 2021 Planned End Date changed from 1 May 2021 to 1 May 2022.
- 29 Nov 2021 Planned primary completion date changed from 1 May 2021 to 1 May 2022.